Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8679870 | Alzheimer's & Dementia | 2018 | 7 Pages |
Abstract
We believe this to be the first demonstration of myelin loss in MCI, Alzheimer's disease, and vascular dementia using a method that provides a quantitative magnetic resonance imaging-based measure of myelin. Our findings add to the emerging evidence that myelination may represent an important biomarker for the pathology of MCI and dementia. This study supports the investigation of the role of myelination in MCI and dementia through use of this quantitative magnetic resonance imaging approach in clinical studies of disease progression, and relationship of functional status to myelination status. Furthermore, mapping MWF may permit myelin to serve as a therapeutic target in clinical trials.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Mustapha Bouhrara, David A. Reiter, Christopher M. Bergeron, Linda M. Zukley, Luigi Ferrucci, Susan M. Resnick, Richard G. Spencer,